Daniel Wattier

Biography

Dan was co-founder of Valocor Therapeutics and led that company as CEO from inception until its acquisition by Dermira Inc. in 2011. Prior to Valocor, Dan was VP Marketing at QLT and served as President of its QLT Specialty Medicine division. Dan previously held senior positions in several pharma/biotech companies including Pfizer, Merck and Johnson & Johnson. Notably at Centocor Inc, Dan was responsible for the US commercial launch of Remicade, which was acquired by Johnson & Johnson, and is now the company’s largest selling drug with over $8B in annual sales worldwide. Dan currently serves on the Board of BIOTECanada and acts as Chair of the Emerging Companies Advisory Board. Dan was co-founder of Valocor Therapeutics and led that company as CEO from inception until its acquisition by Dermira Inc. in 2011. Prior to Valocor, Dan was VP Marketing at QLT and served as President of its QLT Specialty Medicine division. Dan previously held senior positions in several pharma/biotech companies including Pfizer, Merck and Johnson & Johnson. Notably at Centocor Inc, Dan was responsible for the US commercial launch of Remicade, which was acquired by Johnson & Johnson, and is now the company’s largest selling drug with over $8B in annual sales worldwide. Dan currently serves on the Board of BIOTECanada and acts as Chair of the Emerging Companies Advisory Board.

Research Interest

Clinical Pharmacy  Pharmaceutical Administration Medicinal Chemistry